HICKSVILLE, NY -- January 31, 2019 -- InvestorsHub NewsWire
-- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the
“Company”), a developer, manufacturer and seller of a
variety of Cannabidiol (Hemp) based products such as oils, creams,
moisturizers, chews, isolate, gel caps, concentrate and water,
announced today the launch and availability of a revolutionary
Sustained Acoustic Medicine (“SAM”) wellness solution. SAM, along
with its proprietary CBD Gel Capture Patches, is proven in
accelerating tissue healing and chronic pain reduction and is
reimbursable by health insurance companies.
The SAM Pro 2.0 is the first and only FDA cleared wearable
low-intensity ultrasound device delivering multi-hour treatment to
accelerate healing and improve function for musculoskeletal
injuries (muscle, tendon, ligament) and reducing chronic pain
(without opioid pain medication).
Canbiola and its Duramed subsidiary have
attained exclusive distribution of SAM Pro 2.0 in the United States
for no-fault insurance. Under its agreement with Sam International
and ZetrOZ Systems, Canbiola is committed to purchasing 100 units
per month starting in January and ramping to 150 units per month by
June, for a total of 1,650 units for 2019.
Canbiola’s marketing strategy is to provide
equipment and services to both medical offices as well as direct to
consumer. We are presently billing and collecting from the
insurance companies at $58 per day per unit. Given discussions with
the medical community, including doctors and patients, the Company
believes the patient will use the Sam unit and pads for an average
of 35 days per cycle and that each unit will cycle an estimated 7
times per year. Thus, each unit potentially provides $14,210 in
gross rental revenue per year.
Canbiola Chief Executive Officer Marco
Alfonsi, commented, “We are very excited in achieving this
milestone of launching a revolutionary solution that addresses a
much-needed void in the market to accelerate tissue healing and
chronic pain reduction. Our proprietary CBD gels coupled with the
unique SAM delivery system, which we have exclusive U.S. rights
within no-fault insurance to, will potentially drive our
acceleration of both revenues and gross margins over the next
twelve months.”
About Canbiola, Inc.
Canbiola, Inc. (OTCQB: CANB)
is a developer, manufacturer and seller of a variety of
Cannabidiol (Hemp) based products such as oils, creams,
moisturizers, chews, vapes, isolate, gel caps, concentrate and
water. Canbiola has developed its own line of proprietary products
as well as seeking synergistic value through acquisitions in the
CBD and the medical cannabis industry. Cannabis is currently
federally illegal and has legalized for medical purposes in some
form in a limited number of states, but pure CBD products are legal
in all 50 states. For more information about Canbiola, Inc.,
please visit: https://canbiola.com
Forward-Looking
Statements
Forward-looking statements and risks and
uncertainties discussed in this letter contain forward-looking
statements. The words "anticipate," "believe," "estimate," "may,"
"intend," "expect," and similar expressions identify such
forward-looking statements. Expected, actual results, performance,
or achievements could differ materially from those contemplated,
expressed, or implied by the forward-looking statements contained
herein. Forward-looking statements are subject to a number of risks
and uncertainties, including but not limited to, risks and
uncertainties associated with, among other things, the impact of
economic, competitive, and other factors affecting our operations,
markets, products, and performance. The matters discussed herein
should not be construed in any way, shape or manner of our future
financial condition or stock price.
CONTACT INFORMATION:
Canbiola Investor Relations
Email: IR@canbiola.com
Phone: (516) 595-9544
Website: http://www.canbiola.com
Follow us on Twitter and Facebook
